image credit: Flickr

Bayer data at ESMO 2019 highlights innovation in cancer research

September 20, 2019

Bayer will present new data from the company’s expanding oncology business at the European Society for Medical Oncology (ESMO) Congress 2019, taking place September 27 to October 1 in Barcelona, Spain. The presentations to be featured at ESMO 2019 span data on approved therapies as well as new research from Bayer’s early and late-stage oncology pipeline compounds.

New data on durability of response in adult and pediatric patients with TRK fusion cancer treated with a precision medicine agent, Vitrakvi® (larotrectinib) will be highlighted in a poster discussion. Vitrakvi was approved by the U.S.

Read More on PR Newswire